Zenocutuzumab Shows Efficacy in Patients with Advanced NRG1 Fusion-positive Cancers By Ogkologos - February 19, 2025 795 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the eNRGy study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR ESMO Publishes First-Ever Guidance on Validation Requirements for AI-Based Biomarkers in... November 18, 2025 To Treat Pancreatic Cancer, Mouse Study Suggests Altering Tumor Microbiome September 9, 2019 Adagrasib Shows Promising Activity as Monotherapy, Even Greater in Combination with... January 11, 2023 2023 ASCO Annual Meeting Research Round Up: New Research in Treating... September 28, 2023 Load more HOT NEWS Weekend in New England New on NCI’s Websites for March 2021 Neoadjuvant Toripalimab Combined with Axitinib Demonstrates a Promising Pathologic Response Rate... Grandma Saves Her Money To Put Up A Billboard For Everyone...
